295 related articles for article (PubMed ID: 15613700)
1. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Sanderson K; Scotland R; Lee P; Liu D; Groshen S; Snively J; Sian S; Nichol G; Davis T; Keler T; Yellin M; Weber J
J Clin Oncol; 2005 Feb; 23(4):741-50. PubMed ID: 15613700
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
[TBL] [Abstract][Full Text] [Related]
5. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
9. Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.
Chiong B; Wong R; Lee P; Delto J; Scotland R; Lau R; Weber J
J Immunother; 2004; 27(5):368-79. PubMed ID: 15314545
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Hersey P; Menzies SW; Coventry B; Nguyen T; Farrelly M; Collins S; Hirst D; Johnson H
Cancer Immunol Immunother; 2005 Mar; 54(3):208-18. PubMed ID: 15449035
[TBL] [Abstract][Full Text] [Related]
12. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
13. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Attia P; Phan GQ; Maker AV; Robinson MR; Quezado MM; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Restifo NP; Haworth LR; Levy C; Mavroukakis SA; Nichol G; Yellin MJ; Rosenberg SA
J Clin Oncol; 2005 Sep; 23(25):6043-53. PubMed ID: 16087944
[TBL] [Abstract][Full Text] [Related]
15. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Atzpodien J; Fluck M; Reitz M
Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
[TBL] [Abstract][Full Text] [Related]
16. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 blockade: unveiling immune regulation.
Dranoff G
J Clin Oncol; 2005 Feb; 23(4):662-4. PubMed ID: 15613692
[No Abstract] [Full Text] [Related]
18. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]